On the Record · Jazz Pharmaceuticals
Jazz Pharmaceuticals acquisitions, on the record
The businesses Jazz Pharmaceuticals bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
GW Pharmaceuticals plc (GW acquisition)Word for word“The total consideration paid by us for the entire issued share capital of GW was $7.2 billion.” 10-K for 2023 | acquisition | — | The total consideration paid by us for the entire issued share capital of GW was $7.2 billion. |
Epidiolex (acquired as part of GW acquisition)Word for word“We acquired Epidiolex (Epidyolex outside the U.S.) in May 2021 as part of our acquisition of GW, which we refer to as the GW acquisition, which expanded our growing neuroscience business with a global, high-growth childhood-onset epilepsy franchise.” 10-K for 2023 | acquisition | May 2021 | — |
Zepzelca U.S. development and commercialization rights (PharmaMar license)Word for word“We acquired U.S. development and commercialization rights to Zepzelca in early 2020, and launched six months thereafter, with an indication for treatment of patients with SCLC with disease progression on or after platinum-based chemotherapy.” 10-K for 2023 | acquisition | early 2020 | — |
Zanidatamab rights (Zymeworks Inc. subsidiary license)Word for word“We acquired our exclusive development and commercialization rights to Zanidatamab in 2022 through an exclusive licensing agreement with a subsidiary of Zymeworks Inc., or Zymeworks, providing development and commercialization rights to Zanidatamab across all indications in the U.S., Europe, Japan and all other territories except for those Asia/Pacific territories previously licensed by Zymeworks.” 10-K for 2023 | acquisition | 2022 | — |
JZP898 (license from Werewolf Therapeutics, Inc.)Word for word“We acquired rights to JZP898 from Werewolf Therapeutics, Inc., or Werewolf, in 2022 under an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize Werewolf's investigational WTX-613, now referred to as JZP898.” 10-K for 2023 | acquisition | 2022 | — |
Cavion, Inc.Word for word“We acquired suvecaltamide in our acquisition of Cavion, Inc., or Cavion, a clinical-stage biotechnology company, in August 2019.” 10-K for 2023 | acquisition | August 2019 | — |
JZP441 (Sumitomo Pharma Co., Ltd. licensing agreement)Word for word“In May 2022, we announced that we had entered into a licensing agreement with Sumitomo Pharma Co., Ltd, or Sumitomo, to acquire exclusive development and commercialization rights in the U.S., Europe and other territories for DSP-0187, now referred to as JZP441.” 10-K for 2023 | acquisition | May 2022 | — |
Redx Pharma plc (JZP815 portfolio and Ras/Raf/MAP kinase program purchased from Redx)Word for word“Through a collaboration agreement and an asset purchase agreement with Redx in 2019, we acquired a portfolio of U.S. and non-U.S. patents and patent applications, including rights relating to compositions and methods of using JZP815.” 10-K for 2023 | acquisition | 2019 | — |
Defibrotide rights for VOD in North, Central and South America (Sigma-Tau Pharmaceuticals, Inc.)Word for word“We acquired the rights to defibrotide for the treatment and prevention of VOD in North America, Central America and South America from Sigma-Tau Pharmaceuticals, Inc. in 2014.” 10-K for 2023 | acquisition | 2014 | — |
Pfenex, Inc. (worldwide rights including Rylaze patent rights)Word for word“In 2016, we obtained worldwide rights from Pfenex, Inc., or Pfenex, including Pfenex’s patent rights relating to Rylaze, to develop and commercialize multiple early-stage hematology product candidates, including a license to two U.S. process patents relating to Rylaze, with respective expirations in 2026 and 2038.” 10-K for 2023 | acquisition | 2016 | — |
GW Pharmaceuticals plcWord for word“The total consideration paid by us for the entire issued share capital of GW was $7.2 billion.” 10-K for 2024 | acquisition | — | $7.2 billion |
Azur PharmaWord for word“On January 18, 2012, the businesses of Jazz Pharmaceuticals, Inc. and Azur Pharma were combined in a merger transaction, in connection with which Azur Pharma was re-named Jazz Pharmaceuticals plc and we became the parent company of and successor to Jazz Pharmaceuticals, Inc.” 10-K for 2024 | merger | January 18, 2012 | — |
Zepzelca U.S. development and commercialization rights (PharmaMar)Word for word“We acquired U.S. development and commercialization rights to Zepzelca in early 2020, and launched six months thereafter, with an indication for treatment of patients with SCLC with disease progression on or after platinum-based chemotherapy.” 10-K for 2024 | acquisition | early 2020 | — |
Ziihera rights (Zymeworks subsidiary)Word for word“We acquired our exclusive development and commercialization rights to Ziihera in 2022 through a licensing agreement with a subsidiary of Zymeworks providing development and commercialization rights to zanidatamab across all indications in the U.S., Europe, Japan and all other territories except for those Asia/Pacific territories previously licensed by Zymeworks.” 10-K for 2024 | acquisition | 2022 | — |
JZP898 rights (Werewolf)Word for word“We acquired rights to JZP898 from Werewolf in 2022 under an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize Werewolf's investigational WTX-613, now referred to as JZP898.” 10-K for 2024 | acquisition | 2022 | — |
JZP441 license (Sumitomo)Word for word“In May 2022, we announced that we had entered into a licensing agreement with Sumitomo to acquire exclusive development and commercialization rights in the U.S., Europe and other territories for DSP-0187, now referred to as JZP441.” 10-K for 2024 | agreed acquisition | May 2022 | — |
defibrotide rights (Sigma-Tau Pharmaceuticals, Inc.)Word for word“We acquired the rights to defibrotide for the treatment and prevention of VOD in North America, Central America and South America from Sigma-Tau Pharmaceuticals, Inc. in 2014.” 10-K for 2024 | acquisition | 2014 | — |
Redx (JZP815 and Ras/Raf/MAP kinase program)Word for word“Through a collaboration agreement and an asset purchase agreement with Redx in 2019, we acquired a portfolio of U.S. and ex-U.S. patents and patent applications, including rights relating to compositions and methods of using JZP815.” 10-K for 2024 | acquisition | 2019 | — |
PfenexWord for word“In 2016, we obtained worldwide rights from Pfenex, including Pfenex's patent rights relating to Rylaze, to develop and commercialize multiple early-stage hematology product candidates, including a license to two U.S. process patents relating to Rylaze, with respective expirations in 2026 and 2038.” 10-K for 2024 | acquisition | 2016 | — |
ChimerixWord for word“We completed the Chimerix Acquisition in April 2025 for a total of cash consideration of $944.2 million, adding Modeyso (dordaviprone), a protease activator of the mitochondrial ClpP that also inhibits DRD2, to our rare oncology portfolio.” 10-K for 2025 | acquisition | April 2025 | $944.2 million |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Cash received from selling businesses | Goodwill from acquisitions |
|---|---|---|---|
| 2016-12-31 | $1.5 billion | $0 | $252.8 million |
| 2017-12-31 | $0 | $0 | — |
| 2018-12-31 | $0 | — | — |
| 2019-12-31 | $0 | — | — |
| 2020-12-31 | $0 | $14.3 million | — |
| 2021-12-31 | $6.23 billion | $0 | $933.2 million |
| 2022-12-31 | $0 | $53 million | — |
| 2023-12-31 | $0 | $0 | — |
| 2024-12-31 | — | $0 | — |
Deal filings since 2016
- 2026-09-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2026-08-31 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2026-08-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-04-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-03-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-03-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-11-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-09-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-07-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-01-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-12-05 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2021-05-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-05-05 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2021-04-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-04-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-02-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-06-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-01-22 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2019-12-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-04-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-10-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-08-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-07-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-04-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-07-12 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2016-05-31 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Jazz Pharmaceuticals’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-24. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.